| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | 4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride, AG 1517, PD 153035, SU 5271, ZM 252868, PD 153,035, SU 5271, 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline |
| Cas No. | |
| Form | White to off-white solid |
| Molecular Weight | |
| Product Type | |
| Purity | |
| Shipping | |
| SMILES | |
| Solubility | Soluble in DMSO |
| Source | Synthetic |
| Storage |
AG 1517 is a potent and selective ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR signaling plays a critical role in regulating cell proliferation, survival, and differentiation, and its dysregulation has been implicated in various pathological conditions, including cancer and neurodegeneration.
In the context of neuroscience, EGFR is increasingly recognized for its involvement in neuroinflammatory responses, glial cell activation, and neuronal survival. Overactivation of EGFR pathways has been linked to oxidative stress and excitotoxicity—key contributors to the progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. By selectively inhibiting EGFR, AG 1517 offers a targeted approach to modulating these detrimental signaling cascades.
Moreover, EGFR inhibition may influence neurogenesis and synaptic plasticity, processes essential for cognitive function and brain repair. AG 1517’s cell-permeable nature enhances its utility in both in vitro and in vivo models, making it a valuable tool for dissecting EGFR-mediated mechanisms in the central nervous system.
While originally developed for oncology, AG 1517 is gaining traction in neurobiology as a candidate for exploring therapeutic strategies aimed at reducing neuroinflammation, promoting neuronal resilience, and mitigating the molecular drivers of neurodegeneration.
Classification: Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity-single exposure (Category 3)
Safety Phrases:
- S22 - Do not breathe dust.
- S24/25 - Avoid contact with skin and eyes.
- S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
- H301 Toxic if swallowed.
- H315 Causes skin irritation.
- H318 Causes serious eye damage.
- H335 May cause respiratory irritation
Precautionary statements:
- P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
- P280 Wear protective gloves/ eye protection/ face protection.
- P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician.
- P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
AG 1517 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-427)
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close
equivalents, or discuss custom synthesis with the right QC documentation (RUO).
